BRAF and melanoma: Moreover, melanoma cells maintain the high glycolytic profile by activating the MAPK and (PI3K)/ Akt/mTORC1 signaling pathways (by means of V600E mutation activation in BRAF gene or PTEN inactivation) by competing with effector T cells for glucose.